Combination Therapy of TGF-β Blockade and Commensal-derived Probiotics Provides Enhanced Antitumor Immune Response and Tumor Suppression
2019; Ivyspring International Publisher; Volume: 9; Issue: 14 Linguagem: Inglês
10.7150/thno.35131
ISSN1838-7640
AutoresLinlin Shi, Jianyong Sheng, Mengli Wang, Han Luo, Jun Zhu, Bixiang Zhang, Zhi Liu, Xiangliang Yang,
Tópico(s)Pancreatic and Hepatic Oncology Research
ResumoGalunisertib (Gal) is a transforming growth factor (TGF-β) blockade which is being investigated as a potential tumor immunotherapy candidate drug in clinical trials. However, primary or acquired resistance is often found in the recruited cancer patients, which limits its clinical application. Tumor immune microenvironment can be regulated by intestinal microbiota, leading to different therapeutic outcomes. It is hypothesized that manipulation of cancer patients' intestinal microbiome in the early stage of therapy may be a promising strategy to improve the therapeutic efficacy of Gal.
Referência(s)